🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A paper published in Nature presents a comprehensive map of the spatiotemporal heterogeneity of the human proteome by integrating proteomic imaging, transcriptomics and pseudotime measurements of individual cells across the cell cycle. go.nature.com/3sqLqmF

APOBEC3A mutations are even more common than we first thought! Our new study from the lab demonstrates how APOBEC3A promotes mutations outside the canonical TC motif to generate driver and passenger mutations in tumors. nature.com/articles/s4146…

Last week, LCRF supporters toured the Hata Lab at MassGeneral Medicine with Aaron Hata, MD, PhD (4th from left) and Hideko Isozaki, PhD (2nd from left)! LCRF is proud to support this work on preventing drug resistance in non-small cell #lungcancer. Learn more: lcrf.org/ndswo.

APOBEC3A (RNA-editing enzyme) may be key player in TKI resistance. Great talk by Hideko Isozaki MassGeneral Medicine on role of APOBEC3A in drug-tolerant persistent state, & inducing both early & late resistance to TKIs #AACR22 #LCSM

How a therapy for cancer can "perversely increase the adaptive mutability of cancer cells" nature.com/articles/s4158… nature Hideko Isozaki Mass General Cancer Center

A3A Spurs Evolution of Drug-Tolerant Persister Cells in Response to Targeted Therapies. Kudos to Hideko Isozaki from Aaron Hata's lab. Delighted to have contributed to this first study demonstrating the role of A3A in promoting drug resistance. nature.com/articles/s4158…

Adaptive mutability is well known in antibiotic resistance. Cancer cells under oncogene inhibition can undergo hypermutation by upregulating APOBEC3A and eventually make a breakthrough. Was my great pleasure to make a small contribution. Kudos to Hideko Isozaki, Mike and Aaron!

We’re delighted to share our new paper, “Therapy-induced APOBEC3A drives evolution of persistent cancer cells”! Thanks to all of you who have supported this project! Lung Cancer Research Foundation LUNGSTRONG Mass General Cancer Center nature.com/articles/s4158…

Nice review about APOBEC3A from Science written by @Dereklowe! One Way Tumor Cells Fight Back | Science | AAAS science.org/content/blog-p…

Results from a study funded by LCRF may have uncovered a potential therapeutic strategy to prevent or delay acquired resistance to #LungCancer targeted therapy. Hideko Isozaki published this work in the scientific journal, nature. Read more: LCRF.org/isozaki

Our study on the SWI/SNF and resistance in #EGFR mutant #LungCancer is out today in Cancer Cell! This is the work of claudia.gentile, myself, and many other outstanding scientists during my #postdoc Yale Cancer Center. #LCSM 🔗cell.com/cancer-cell/fu… #Tweetorial or #Xtorial?👇 1/15

Now online! APOBEC3A and APOBEC3B drive distinct mutational landscapes in tumors. We showed how A3A and A3B substrate preferences for different hairpin structures can be exploited to identify patients' tumors with mutations caused by either A3A or A3B. nature.com/articles/s4146…

JREC-IN Portal : Postdoctoral Fellow (Endocrinology/Stem Cell Field) jrecin.jst.go.jp/seek/SeekJorDe…

I'm pleased to announce I started my laboratory as a Professor at Kanazawa University Cancer Research Institute in Japan! My laboratory studies how cancers evolve and progress, especially focusing on innate immunity and genomic instability. We'er hiring an Assistant Professor!

The position of Assistant Professor at Kanazawa University Cancer Research Institute is now opening! 金沢がん進展制御研究所 ゲノム生物学分野 (主任: 磯崎) 助教候補者を募集しております。 研究室ホームページ isozakilab.com cancer.or.jp/modules/news/i…

演題募集期間を延長しましたのでご案内します。 4月18日(金)までの延長です。 多くの皆様のご応募をお待ちしております！！ ＃JCA84　＃演題募集延長

演題募集期間を延長しました！ 今回が最後の延長となります。 たくさんのご応募をお待ちしております。 ※シンポジウム公募枠については、 　本日正午にて締切ました。 #JCA84 #演題募集期間延長